Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 9/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10083355 | 1.00 | OPRK1 (0.56) | OPRK1OPRD1OPRM1CYP2D6POLB | |
| SCHEMBL15380395 | 0.91 | OPRK1 (0.55) | OPRK1OPRD1OPRM1CYP2D6POLB | |
| SCHEMBL433098 | 0.91 | OPRK1 (0.55) | OPRK1OPRD1OPRM1CYP2D6POLB | |
| SCHEMBL432352 | 0.87 | OPRK1 (0.60) | OPRK1OPRD1OPRM1CYP2D6 | |
| SCHEMBL433167 | 0.87 | OPRK1 (0.42) | OPRK1OPRD1OPRM1CYP2D6ALDH1A1 | |
| SCHEMBL10083352 | 0.87 | OPRK1 (0.42) | OPRK1OPRD1OPRM1CYP2D6ALDH1A1 | |
| SCHEMBL435448 | 0.87 | CCR2 (0.43) | OPRK1OPRD1OPRM1CYP2D6ALDH1A1 | |
| SCHEMBL10083346 | 0.87 | CCR2 (0.43) | OPRK1OPRD1OPRM1CYP2D6ALDH1A1 | |
| SCHEMBL435831 | 0.85 | HSD11B1 (0.50) | ALDH1A1KMT2AGPR88NPC1 | |
| SCHEMBL15385492 | 0.85 | HSD11B1 (0.50) | ALDH1A1KMT2AGPR88NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | claimed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | claimed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OPRD1 | OPRK1 1/4885OPRD1 3/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.